BarentsKrans advises Angelini Pharma on the acquisition of the shares in Arvelle Therapeutics

BarentsKrans has advised Angelini Pharma on the acquisition of the shares in Arvelle Therapeutics. Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS (Central Nervous System) disorders. “At Angelini Pharma, we are thrilled to sign this promising agreement and are enthusiastic about the commitment and work that our
Read more ›

BarentsKrans advises the sell side on the sale of Yellowstar

BarentsKrans has advised the sell side on the sale and transfer of the shares in Yellow Star Solution Holding B.V. to ICT Group N.V. Yellowstar, founded in 2009 and located in Barendrecht, makes supply chains fully predictable and transparent. Yellowstar also realises customized software solutions for transport management systems, dynamic planning boards, terminal operating systems,
Read more › judgment: jurisdiction for actions based on an abuse of a dominant position

On 24 November 2020, the European Court of Justice (ECJ) ruled that the German hotel Wikingerhof, which used the platform, may bring proceedings based on an abuse of a dominant position before the courts of Germany, although defendant was domiciled in the Netherlands. The decision stems from the questions of the German referring
Read more ›

BarentsKrans advises on the sell side of the acquisition of Sanidump

BK has advised on the sell side of the acquisition of Sanidump by the FG-group, the holding company of the Dutch franchise formulas,, Sanistunter and Keukenstunter. Sanidump operates 41 megastores and is the largest and fastest growing independent sanitary shop in the Netherlands and has over 24 years of experience in that field.
Read more ›

Pharma update | Dutch Court of Appeal: Pemetrexed patent Eli Lilly valid and infringed

In its judgment of 27 October 2020, the Court of Appeal of The Hague found that the generic pemetrexed tromethamine product of Fresenius Kabi Nederland B.V. (“Fresenius”) infringes EP 1 313 508 (‘EP‘508’), held by Eli Lilly and Company (“Lilly”). Yet again a turn of events in Dutch case law, where this issue has been
Read more ›

Pharma update | AstraZeneca ordered to compensate damage health insurer Menzis for enforcing invalid patent

In a groundbreaking judgment of 14 October 2020, the District Court of The Hague ruled that AstraZeneca AB (‘AstraZeneca’) must compensate health insurer Menzis Zorgverzekeraar NV (‘Menzis’) for having enforced a patent that was later invalidated. AstraZeneca owned European patent EP 0 907 364 (“EP 364”) for a sustained-release (XR) formulation of quetiapine, an active
Read more ›

Pharma update | Cross-border preliminary injunction granted regarding deferasirox

At the request of Novartis the Provisions Judge of the District Court of The Hague granted a preliminary injunction against Mylan BV for the alleged imminent infringement of Novartis’ paediatric extension (‘PE’) of Dutch SPC 300248 (‘SPC ‘248’) based on EP 0 914 118 (‘EP ‘118’).The product at issue contains deferasirox as the active ingredient
Read more ›